Use of Fixed Dose Combination (FDC) Drugs in India: Central Regulatory Approval and Sales of FDCs Containing Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), Metformin, or Psychotropic Drugs

PLoS Medicine

Volumn 12, Issue 5, 2015, Pages

  McGettigan, Patricia ^a   Roderick, Peter ^b   Mahajan, Rushikesh ^c   Kadam, Abhay ^c   Pollock, Allyson M ^b  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^b QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^c Foundation for Research in Community Health India   (India)

Author keywords

[No Author keywords available]

Indexed keywords

ALPRAZOLAM; AMITRIPTYLINE; CHLORDIAZEPOXIDE; CHLORPROMAZINE; CLONAZEPAM; DESVENLAFAXINE; DIAZEPAM; ESCITALOPRAM; FLUOXETINE; FLUPENTIXOL; GLIBENCLAMIDE; GLICLAZIDE; GLIMEPIRIDE; GLIPIZIDE; IMIPRAMINE; MELITRACEN; METFORMIN; MIGLITOL; NONSTEROID ANTIINFLAMMATORY AGENT; OLANZAPINE; PIOGLITAZONE; PROPRANOLOL; PSYCHOTROPIC AGENT; RISPERIDONE; ROSIGLITAZONE; TRIFLUOPERAZINE; TRIHEXYPHENIDYL; UNINDEXED DRUG; VILDAGLIPTIN; VOGLIBOSE; DRUG COMBINATION;

ADVISORY COMMITTEE; ARTICLE; CROSS-SECTIONAL STUDY; DRUG APPROVAL; DRUG DOSE; DRUG FORMULATION; DRUG MARKETING; ECOLOGY; FIXED DOSE COMBINATION; INDIA; LICENCE; UNITED KINGDOM; UNITED STATES; DRUG COMBINATION; DRUG LEGISLATION; HUMAN;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; DRUG COMBINATIONS; HUMANS; INDIA; LEGISLATION, DRUG; METFORMIN; PSYCHOTROPIC DRUGS;

EID: 84930536180     PISSN: 15491277     EISSN: 15491676     Source Type: Journal    
DOI: 10.1371/journal.pmed.1001826     Document Type: Article

References (50)

1. Harris G (2014 Apr 14) Medicines made in India set off safety worries. New York Times. http://www.nytimes.com/2014/02/15/world/asia/medicines-made-in-india-set-off-safety-worries.html. Accessed 30 March 2015.
2. European Medicines Agency (2015 Jan 23) GVK Biosciences: European Medicines Agency recommends suspending medicines over flawed studies. http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2015/01/news_detail_002256.jsp&mid=WC0b01ac058004d5c1. Accessed 30 March 2015.
3. Porecha M (2014 Apr 22) Vietnam shows the door to 45 Indian pharma companies. DNA (Diligent Media Corporation). http://www.dnaindia.com/mumbai/report-vietnam-shows-the-door-to-45-indian-pharma-companies-1980761. Accessed 30 March 2015.
4. Ministry of Health and Family Welfare (2003) Report of the expert committee on a comprehensive examination of drug regulatory issues, including the problem of spurious drugs. http://planningcommission.nic.in/reports/genrep/health/Final_Report_mashelkar.pdf. Accessed 30 March 2015.
5. Community Development Medicinal Unit, Health Action International Asia Pacific (2010 Dec 15) Report on research project: ‘fixed-dose combination in India, inception—marketing—a study’. http://www.cdmuindia.org/Pdf-files/Final-report-IFDCs.pdf. Accessed 30 March 2015.
6. Department-Related Standing Committee on Health and Family Welfare (2012 May) 59th report on the functioning of the Central Drugs Standard Control Organization (CDSCO). New Delhi: Parliament of India. http://164.100.47.5/newcommittee/reports/englishcommittees/committee%20on%20health%20and%20family%20welfare/59.pdf. Accessed 30 March 2015.
7. (2012) Drug regulation in India—the time is ripe for change. Lancet 379: 1852. http://www.thelancet.com/pdfs/journals/lancet/PIIS0140-6736%2812%2960792-2.pdf. Accessed 30 March 2015.
8. World Health Organization (2005) Annex 5: guidelines for registration of fixed dose combination medicinal products. WHO Technical Report Series, No. 929. http://apps.who.int/medicinedocs/documents/s19979en/s19979en.pdf. Accessed 30 March 2015.
9. Jain N, Akarte A, Deshmukhk P, Kannojia P, Garund N, et al. (2009) Rationality of fixed dose combinations: an Indian scenario. Pharma Res 1: 158–168. http://thepharmaresearch.info/documents/PDF/TPR-090120.pdf. Accessed 30 March 2015.
10. Medicines and Healthcare Products Regulatory Agency (2012) Summary of product characteristics: chlorpromazine 100mg tablets. http://www.mhra.gov.uk/home/groups/spcpil/documents/spcpil/con1407476358070.pdf. Accessed 30 March 2015.
11. Medicines and Healthcare Products Regulatory Agency (2012) Summary of product characteristics: stelazine 5 mg tablets or trifluoperazine 5 mg tablets. http://www.mhra.gov.uk/home/groups/spcpil/documents/spcpil/con1389947107511.pdf. Accessed 30 March 2015.
12. National Institute for Health and Care Excellence (2015) British National Formulary. Available (UK only): http://www.evidence.nhs.uk/formulary/bnf/current. Accessed 30 March 2015.
13. Singh GN (2013 Jul 5) To: all state/UT drug controllers. Subject: approval of the safety and efficacy of fixed dose combinations (FDCs) permitted for manufacture for sale in the country without due approval from the office of DCG(I)—regarding. F. No. 4-01/2013-DC (Misc13-PSC). http://www.cdsco.nic.in/writereaddata/Approval_of_the_safety_and%20efficacy_FDC.pdf. Accessed 30 March 2015.
14. Drugs Controller General (India) (2013) Consolidated list of FDCs licensed by SLAs but not permitted by DCG(I). New Delhi: Drugs Controller General (India).
15. Government of India Ministry of Health and Family Welfare (2003) The Drugs and Cosmetics Act and Rules. http://www.emergogroup.com/sites/default/files/file/india-drugs-and-cosmetics-act-1940-act-no-23.pdf. Accessed 30 March 2015.
16. Central Drugs Standard Control Organization (2013) Fixed dose combinations approved by DCG(I) since 1961 till December, 2013. http://www.cdsco.nic.in/writereaddata/FDC_approved_dcgi%281%29_2013.pdf. Accessed 30 March 2015.
17. Medicines and Healthcare Products Regulatory Agency (2015) Medicines information: SPC & PILs. http://www.mhra.gov.uk/Safetyinformation/Medicinesinformation/SPCandPILs/index.htm. Accessed 30 March 2015.
18. US Food and Drug Administration (2015) Orange book: approved drug products with therapeutic equivalence evaluations. http://www.accessdata.fda.gov/scripts/cder/ob/docs/tempai.cfm?firstRec=101. Accessed 30 March 2015.
19. (2015) Monthly Index of Medical Specialties. http://www.mims.co.uk. Accessed 30 March 2015.
20. AIOCD AWACS (2015) Products and offering: PharmaTrac. http://www.aiocdawacs.com/ProductDetail.aspx. Accessed 30 March 2015.
21. Lang TA, Altman DG (2013) Biostatistical reporting for articles reported in biomedical journals: the “Statistical Analyses and Methods in the Published LITERATURE” or the SAMPL guidelines. Equator Network. http://www.equator-network.org/wp-content/uploads/2013/07/SAMPL-Guidelines-6-27-13.pdf. Accessed 30 March 2015.
22. Government of India Ministry of Health and Family Welfare (2014) Indian pharmacopoeia 2014. Book No 0048. Ghaziabad (India): Indian Pharmacopoeia Commission.
23. European Medicines Agency (2011 Jun 23) European Medicines Agency concludes review of systemic nimesulide-containing medicines. http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2011/06/news_detail_001285.jsp&mid=WC0b01ac058004d5c1. Accessed 7 April 2015.
24. European Medicines Agency (2014 Jan 17) European Medicines Agency recommends restricting use of thiocolchicoside by mouth or injection. http://www.ema.europa.eu/docs/en_GB/document_library/Referrals_document/Thiocolchicoside-containing_medicines/WC500155447.pdf. Accessed 30 March 2015.
25. European Medicines Agency (2009 Jun 25) European Medicines Agency recommends withdrawal of dextropropoxyphene-containing medicines. http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2009/11/news_detail_000074.jsp&mid=WC0b01ac058004d5c1. Accessed 30 March 2015.
26. United Nations Department of Economic and Social Affairs (2005) Consolidated list of products whose consumption and/or sale have been banned, withdrawn, severely restricted or not approved by governments, twelfth issue. http://apps.who.int/medicinedocs/en/d/Js16780e/. Accessed 30 March 2015.
27. Das S (2014 Jul 25) Lundbeck to seek legal recourse after health ministry bans Deanxit again. Economic Times. http://articles.economictimes.indiatimes.com/2014-07-25/news/52026547_1_lundbeck-deanxit-franxit. Accessed 30 March 2015.
28. Hunter ML, , editor (2012) The global investigative journalism casebook. UNESCO series on journalism education. United Nations Educational, Scientific and Cultural Organization. http://unesdoc.unesco.org/images/0021/002176/217636e.pdf. Accessed 7 April 2015.
29. World Health Organization (2005) Thioridazine withdrawn due to poor benefit/risk profile. WHO Pharmaceuticals Newsletter 2005, No 01. http://apps.who.int/medicinedocs/en/d/Js8116e/1.7.html. Accessed 30 March 2015.
30. Hartikainen S, Loonroos E, Louhivouri K, (2007) Medication as a risk factor for falls: critical systematic review. J Gerontol A Biol Sci Med Sci 62: 1172–1181. 17921433
31. Jesani A, (2012) Ethics of expert opinion and the observations of the department-related parliamentary standing committee on the CDSCO. J Pharmacol Pharmacother 3: 297–299. doi: 10.4103/0976-500X.103684 23326098
32. BioSpectrum Bureau (2013 Aug 19) India approved 26 drugs without clinical trials. http://www.biospectrumasia.com/biospectrum/news/193708/india-approved-26-drugs-clinical-trials#.Uv9z0oXrCw8. Accessed 30 March 2015.
33. Datapharm (2015) eMC [database]. http://www.medicines.org.uk/emc/. Accessed 30 March 2015.
34. Kshirsagar N, (2005) The pharmacovigilance system in India. Drug Saf 28: 647–650. 15963011
35. Gosh AK, De A, Bala NN, (2011) Current problems and future aspects of pharmacovigilance in India. Int J Pharma Bio Sci 2: 15–28. http://ijpbs.net/volume2/issue1/pharma/_1.pdf. Accessed 30 March 2015.
36. Pharmacovigilance Program of India (2013) AMCs under PvPI. Indian Pharmacopoeia Commission. http://www.ipc.gov.in/PvPI/pv_amcs.html. Accessed 30 March 2015.
37. (2015) CIMS India [database]. http://www.cimsasia.com/. Accessed 30 March 2015.
38. Health and Social Care Information Centre (2013) Prescription cost analysis: England 2012. http://www.hscic.gov.uk/catalogue/PUB10610/pres-cost-anal-eng-2012a-rep.pdf. Accessed 30 March 2015.
39. Selvaraj S (2013 Jul 14) Another bitter pill for patients. The Hindu. http://www.thehindu.com/opinion/op-ed/another-bitter-pill-for-patients/article4912747.ece. Accessed 30 March 2015.
40. Pradhan R (2013 Nov 13) Medicines prices: DPCO loopholes will deny cheaper essential drugs. Moneylife. http://www.moneylife.in/article/effect-of-drug-prices-control-order-dpco-2013-on-medicines/35249.html. Accessed 30 March 2015.
41. Shetty S, Modi R (2013) India Pharma Inc.: changing landscape of the Indian pharma industry. Pricewaterhouse Coopers; Confederation of Indian Industry. http://www.pwc.in/assets/pdfs/publications/2013/changing-landscape-of-the-indian-pharma-industry.pdf. Accessed 30 March 2015.
42. Singh GN (2013 Jan 15) To: all state/UTs drugs controllers. Subject: approval of the safety and efficacy of fixed dose combinations (FDCs) permitted for manufacture for sale in the country without due approval from the office of DCG(I)—regarding. F. No. 4-01/2013-DC (Misc13-PSC). http://www.cdsco.nic.in/writereaddata/Approval_of_the_safety_and_efficacy_of_FDC.pdf. Accessed 30 March 2015.
43. Chaudhury RR (2013 Jul) Report of the Prof. Rajnit Roy Chaudhury Expert Committee to formulate policy and guidelines for approval of new drugs, clinical trials and banning of drugs. http://www.indiaenvironmentportal.org.in/files/file/clinical%20trials1.pdf. Accessed 30 March 2015.
44. Central Drugs Standard Control Organization (2013 Jun) Policy guidelines for the approval of fixed dose combinations (FDCs) in India. http://www.mohfw.nic.in/WriteReadData/l892s/6404452866Kokate%20Report.pdf. Accessed 30 March 2015.
45. Singh GN (2014 Jun 5) To: all state/UTs drugs controllers. Subject: approval of the safety and efficacy of fixed dose combinations (FDCs) permitted for manufacture for sale in the country without due approval from the office of DCG(I)—regarding. F. No. 4-01/2013-DC (Misc13-PSC). http://www.cdsco.nic.in/writereaddata/approvalfdc.pdf. Accessed 30 March 2015.
46. Veerramani SV (2014 Jul 25) To: Shri Lov Verma, IAS. Subject: fixed dose combinations (FDCs). Indian Drug Manufacturers Association. http://www.idma-assn.org/pdf/25-07-2014_Letter_to_Shri_Lov_Verma_Health_Secretary_on_FDCs.pdf. Accessed 30 March 2015.
47. Roderick P, Mahajan R, McGettigan P, Pollock A, Jeffery R, (2014) Need for a new drugs bill. Econ Polit Wkly XLIX (33): 15–19.
48. (2013) The Drugs and Cosmetics (Amendment) Bill of 2013. Government of India. http://www.prsindia.org/uploads/media/Drugs%20and%20Cosmetics/drugs%20and%20cosmetics%20bill.pdf. Accessed 30 March 2015.
49. (2014 Dec 31) The Drugs and Cosmetics (Amendment) Bill of 2015 [draft]. Department of Health and Family Welfare. http://www.cdsco.nic.in/writereaddata/D&%20C%20AMMENDMENT%20BILL%281%29.pdf. Accessed 30 March 2015.
50. Greene JA, Podolsky SH, (2012) Reform, regulation, and pharmaceuticals: the Kefauver-Harris amendments at 50. N Engl J Med 367: 1481–1483. doi: 10.1056/NEJMp1210007 23075174